According to a new survey by iData Research, the majority of cardiologists in the U.S., Europe, China, India, Middle East and Africa would use a bioabsorbable stent for the treatment of coronary angioplasty.

In contrast, the majority of cardiologists in Japan and Latin-America would not use a bioabsorbable stent, thus exemplifying a dramatic difference between geographical regions in usage trends. Japanese and Latin American cardiologists cite a lack of long-term clinical data, early recoil and technical challenges as drawbacks for adopting these new technologies.

 Bioabsorbable stents are expected to enter the U.S. market in 2013 and will reach a value of more than $812 million by 2015. Companies such as Abbott Laboratories, Biosensors International, and REVA Medical have been identified as emerging leaders.

Read more in iData Research’s 3-report global series on the “Markets for Interventional Cardiology Devices” at the link below: